Thanks to the combined work of AIM and the Alzheimer's Association, the federal government has committed to a goal to prevent and effectively treat Alzheimer's disease by 2025. But achieving this goal requires a significant research commitment at the National Institutes of Health (NIH).
AIM has worked with the Alzheimer's Association to propel the U.S. government to rise to this challenge, resulting in more than quadrupling Alzheimer's research funding since the passage of NAPA — including a historic $425 million increase for Alzheimer's research at the NIH for fiscal year 2019. Today, funding for Alzheimer's and dementia related research at the National Institutes of Health (NIH) is $2.4 billion. In September 2019, the Senate Labor-HHS Appropriations Subcommittee proposed a $350 million increase for fiscal year 2020.
As a result of these significant increases, scientists are able to work at a more rapid pace to advance basic disease knowledge, explore ways to reduce risk, uncover new biomarkers for early diagnosis and drug targeting, and develop potential treatments.
But with a new American developing Alzheimer's every 65 seconds, we know a greater investment is needed. The current funding level is still short of the total funding scientists and the U.S. Alzheimer's Advisory Council created by Congress believe is needed to meet the goal of preventing and effectively treating Alzheimer's by 2025.
AIM is asking Congress to approve an additional $350 million increase in Alzheimer's and dementia research funding at the NIH for FY2020.